Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 118750
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.118750
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.118750
Patient-derived organoids: A new platform for mechanism research and drug development of gastric intestinal metaplasia
Jin-Yan Deng, Hong-Bo Du, Division of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
Xiao-Bin Zao, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
Co-first authors: Jin-Yan Deng and Hong-Bo Du.
Author contributions: Deng JY and Du HB jointly contributed to the writing of the main text, they contributed equally to this article, they are the co-first authors of this manuscript; Zao XB was responsible for structural adjustments and revisions to the article; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Xiao-Bin Zao, MD, Assistant Researcher, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5 Haiyuncang Road, Dongcheng District, Beijing 100700, China. a3417@bucm.edu.cn
Received: January 12, 2026
Revised: February 11, 2026
Accepted: March 18, 2026
Published online: August 15, 2026
Processing time: 205 Days and 5.7 Hours
Revised: February 11, 2026
Accepted: March 18, 2026
Published online: August 15, 2026
Processing time: 205 Days and 5.7 Hours
Core Tip
Core Tip: Gastric intestinal metaplasia (GIM) is a precancerous lesion in the process of gastric carcinogenesis. Organoid technology has overcome the limitations of previous models by preserving patient-specific molecular features. A recent study identified taurine as a potential drug for suppressing GIM in patient-derived organoids and mouse models. Future research should prioritize the use of patient-derived organoids to study GIM pathogenesis and advance drug development more precisely.